Core Viewpoint - The company reported a resilient performance in the first half of 2025, achieving revenue of 230 million yuan and a non-net profit of 23.59 million yuan, reflecting a year-on-year growth of 24.89% [1] Group 1: Financial Performance - The company achieved revenue of 230 million yuan in the first half of 2025 [1] - The non-net profit for the same period was 23.59 million yuan, representing a year-on-year increase of 24.89% [1] Group 2: Business Strategy - The company operates in the field of POCT (Point of Care Testing) reagents and instruments, focusing on research, production, and sales [1] - The company has adopted a "dual-wheel drive" strategy, maintaining operational resilience despite increasing uncertainties in overseas markets [1] - In the domestic market, the company has obtained multiple medical device registrations, including products for respiratory virus antigen testing and chest pain triage [1] - The company is expanding its C-end market through the "Anxu Ke" brand on e-commerce platforms, establishing a dual-track development model for B-end and C-end markets [1]